



4TH AUSTRALASIAN CONFERENCE – CANBERRA 2004

# FULL CONFERENCE PROGRAM

**TUESDAY 31 AUGUST 2004**

11.00am	Registration
1.30pm - 3.30pm	<b>Opening Session &amp; Strategic Directions for an Expanding Epidemic</b> Royal Theatre Chairs: Greg Dore & Bill Sievert
1.30pm - 1.40pm	Welcome to the Land speaker - Don Bell
1.40pm - 1.50pm	Greg Dore, Convenor of the 4th Australasian Hepatitis C Conference
1.50pm - 1.55pm	Darrell Crawford of the Gastroenterological Society of Australia
1.55pm - 2.00pm	Jack Wallace of the Australian Hepatitis Council
2.00pm - 2.05pm	Annie Madden of the Australian Injecting and Illicit Drug Users League
2.05pm - 2.10pm	John Hornell of the Hepatitis Foundation of New Zealand
2.10pm - 2.15pm	Tracey Jones of the Australasian Hepatology Associates
2.15pm - 2.30pm	<b>The Hon. Dr Michael Wooldridge, Chair of the Ministerial Advisory Committee on AIDS, Sexual Health and Hepatitis</b>
2.30pm - 3.00pm	<b>Annie Madden, Executive Officer of the Australian Injecting and Illicit Drug Users League</b> Role of people who inject drugs in the response to Hepatitis C
3.00pm - 3.30pm	<b>Geoff Farrell, Robert W Storr Professor of the Storr Liver Unit at Westmead Hospital</b> 15 years of Hepatitis C: lessons learnt and future directions for the Australian response
3.30pm - 4.00pm	Afternoon Tea in the Foyer
4.00pm - 5.30pm	<b>Plenary 1 - Advances in the Understanding of Chronic Viral Hepatitis</b> Royal Theatre Chairs: Michael Beard & Stephen Locarnini
4.00pm - 4.30pm	<b>Michael Lai, Distinguished Professor of Molecular Microbiology and Immunology at The University of Southern California and the Vice President of Academia Sinica</b> Molecular Mechanisms of Pathogenesis of Hepatitis C Infection
4.30pm - 5.00pm	<b>Michael Gale, Assistant Professor in the Department of Microbiology at the University of Texas Southwestern Medical Center</b> HCV and Interferon Resistance, The Virus or the Host
5.00pm - 5.30pm	<b>Solko Schalm, Head of Hepatology at the Erasmus MC University Medical Center, Rotterdam, Netherlands</b> New and Future Treatment of Chronic Hepatitis B
5.30pm - 7.00pm	Welcome Drinks & Exhibition Opening

**WEDNESDAY 1 SEPTEMBER 2004**

<b>7.30am</b>	<b>Registration</b>							
<b>9.00am - 10.30am</b>	<b>Plenary - Improving Access to Hepatitis C Prevention, Treatment and Care for People Who Inject Drugs</b> Royal Theatre Chairs: Jude Byrne & Paul Haber							
<b>9.00am - 9.30am</b>	<b>Charles Henderson, National Manager of the Needle Exchange Program, Christchurch, New Zealand</b> Priorities for Prevention, Treatment and Care							
<b>9.30am - 10.00am</b>	<b>Ingrid van Beek, Director of the Kirketon Road Centre</b> Accessible Primary Care as a Foundation for Improved Health Outcomes							
<b>10.00am - 10.30am</b>	<b>Diana Sylvestre, Assistant Clinical Professor in the Department of Medicine at the University of California, San Francisco, USA</b> Treating Hepatitis C in Drug Injectors							
<b>10.30am - 11.00am</b>	<b>Morning Tea in Exhibition &amp; Poster Area - Exhibition Hall</b>							
<b>11.00am - 12.30pm</b>	<b>Symposium - Clinical Medicine - Hepatitis B: Individualising Patient Therapy</b> Royal Theatre Chairs: Ed Gane & Stephen Locarnini Panel: Solko Schalm, Graham Cooksley, Angeline Bartholomeusz, Joe Sasadeusz, Bill Sievert	<b>Concurrent - Clinical Medicine - Hepatitis B: Individualising Patient Therapy</b>	<b>Concurrent - Epidemiology &amp; Social Research - HCV in IDUs: Risk Behaviour, Transmission and Research Strategies</b>	<b>Concurrent - Public Health &amp; Prevention - Public Health Burden and Responses</b>	<b>Concurrent - Community - Strategies, Approaches &amp; Models</b>	<b>Concurrent - Basic Science - Immunopathogenesis of Viral Hepatitis</b>		<b>Sutherland Theatre</b> Chairs: Michael Gale & Andrew Lloyd
			<b>Bradman Theatre</b> Chairs: Ingrid van Beek & Mary O'Brien	<b>Menzies Theatre</b> Chairs: John Kaldor & Margaret Hellard	<b>Nicholls Theatre</b> Chairs: Jack Wallace & Sharon Caris			

11.00am - 11.20am	Schalm S - The LiverDoc System: A New Form of Consultative Academic Medicine for Hepatitis B&C	11.00am - 11.15am	Middleton M - Trends in Hepatitis C Infection in Australia, 1999-2003	11.00am - 11.15am	Thein H - Health-Related Quality of Life in a Prisoner Population With and Without Chronic Hepatitis C in NSW, Australia	11.00am - 11.15am	Ward J - Increasing Access to Services in NSW for Aboriginal People at Risk of Contracting Infections - A Comprehensive Consultancy in NSW	11.00am - 11.20am	Visvanathan K - TOLL Receptors and Viral Hepatitis
11.20am - 11.40am	Cooksley G - Role of Interferons in Chronic Hepatitis B	11.15am - 11.30am	Aitken C - The Molecular Epidemiology of Hepatitis C Virus in a Social Network of Injecting Drug Users	11.15am - 11.30am	Day C - The Impact of the Heroin Shortage upon Injecting Drug Use and Hepatitis C Infections in NSW	11.15am - 11.30am	Wiggins N - Hepatitis C and the Role of Drug User Organisations	11.20am - 11.34am	Helbig K J - Expression of the CXCR3 Ligand, I-TAC By Hepatocytes in Chronic HCV, and its Correlation with Hepatic Inflammation
11.40am - 12.00pm	Bartholomeusz A - Development of Bioinformatics Programmes for Patient Management	11.30am - 11.45am	Micallef J - Comparison of Incidence of Initial HCV Infection and Reinfection: No Evidence for Protective Immunity	11.30am - 11.45am	McNally S - Now, Later or Never: When to Refer a Patient with Hepatitis C	11.30am - 11.45am	Elek C - Tips, Tools and Techniques: A Practical Workshop for Hepatitis C Educators	11.34am - 11.48am	Harvey CE - Hepatitis C Virus Specific T Cell Effectors in the Blood and Liver of Patients with Chronic HCV Infection Preferentially Express the Chemokine Receptor CXCR6
12.00pm - 12.30pm	Locarnini S - Hepatitis B Case Studies	11.45am - 12.00pm	Thein H - Hepatitis C Prevalence and Risk Behaviours Among High Risk Populations Attending Needle and Syringe Programs in Australia	11.45am - 12.00pm	Hornell J - Preliminary Results of a Two-Year Chronic HBV Follow-Up Programme	11.45am - 12.00pm	Paterson K - A Health Promotion Approach to Hepatitis C	11.48am - 12.02pm	Gaudieri S - Adaptation of Hepatitis C Virus to HLA-Restricted Responses in HLA Diverse Populations
12.30pm - 1.30pm	Lunch in the Exhibition & Poster Area - Exhibition Hall	12.00pm - 12.15pm	Thein H - Hepatitis C Prevalence and Risk Behaviours Among Young Injecting Drug Users	12.00pm - 12.15pm	Richmond J - Does Health Professionals' Hepatitis C Knowledge and Attitudes Impact on the Care they Provide for People with Hepatitis C?	12.00pm - 12.15pm	Treloar C - An Innovative Model for Developing Research Capacity in the Hepatitis C Sector	12.02pm - 12.16pm	Lucas M - Analyses of Successful and Unsuccessful Immune Responses Against Hepatitis C Virus Using MHC Class II Tetramers for the Study of CD4+ T Cells
		12.15pm - 12.30pm	Higgs P - Recruitment: Issues for the Involvement of Injecting Drug Users into Hepatitis C Research	12.15pm - 12.30pm	Watson B - Alcohol Consumption Patterns Amongst Hepatitis C Positive People Receiving Opioid Maintenance Treatment	12.15pm - 12.30pm	Clements D - Celebrating Good Practice - Opportunities for Workplace Change	12.16pm - 12.30pm	Jilbert AR - Resolution of Transient Hepadnavirus Infections is Accompanied By Histologic Evidence of Marked Hepatocyte Death and Liver Regeneration

12.30pm -1.30pm		12.30pm -1.30pm	Workshop - Addressing the Health Needs of People Affected with Hepatitis C : A forum for people Living with and Affected by Hepatitis C Chairs: Sharon Caris & Kerry Paterson	
<b>Plenary - The Expanding Epidemic of Hepatitis C in Australia</b>				
1.30pm -3.00pm			Royal Theatre Chairs: Margaret Hellard & Cheryl Brunton	
1.30pm -2.00pm			Louisa Degenhardt, Senior Lecturer at the National Drug and Alcohol Research Centre Epidemiology of injecting drug use in Australia	
2.00pm -2.30pm			Campbell Aitken, Senior Research Officer at the Burnet Institute Working with Social Networks will Advance Hepatitis C Epidemiology	
2.30pm -3.00pm			Matthew Law, Head of the Biostatistics and Databases Program at the National Centre in HIV Epidemiology and Clinical Research, University of NSW Trends in Long-term Sequelae of HCV Infection in Australia, 2005-2020	
3.00pm -3.30pm			Afternoon Tea in the Exhibition & Poster Area - Exhibition Hall	
3.30pm -5.00pm			Symposium - Clinical Medicine - Improving Treatment Outcomes for People with Hepatitis C Royal Theatre Chairs: Jacqui Richmond & Graham McDonald	
			Concurrent - Basic Science - Hepatitis B Virology Bradman Theatre Chairs: Allison Jillbert & Yvonne Cossart	
			Concurrent - Epidemiology & Social Research - Defining and Addressing Morbidity in Chronic Viral Hepatitis Menzies Theatre Chairs: Bob Batey & Mary O'Brien	
			Concurrent - Community - Community Voices Nicholls Theatre Chairs: Michael Doyle & Nicki Bath	
			Concurrent - Public Health & Prevention - Lessons Learnt from Public Health Interventions Sutherland Theatre Chairs: Cheryl Brunton & Michael Levy	

3.30pm 3.50pm	Sylvestre D - Assessment & Management of Depression in the Setting of Comorbid Addictive Disorders	3.30pm 3.45pm	Mckay R - Interactions Between Hepatitis B and Hepatitis C Virus in a Human Hepatoma Cell Line (HUH-7)	3.30pm 3.45pm	Amin J - Hepatitis B and C and Liver Cancer in New South Wales 1990-2002: A Linkage Study	3.30pm 3.45pm	Harvey EF - Hangin' In: A Peer Education Model for Young Indigenous Drug Users by Young Indigenous Drug Users	3.30pm 3.45pm	Douglas J - Provision of Care to Hepatitis C Positive Inmates in NSW Correctional Centres
3.50pm 4.05pm	Totten L - Shared Care: What Makes it Successful	3.45pm 4.00pm	Ayres A - Characterisation of Lamivudine Resistant Hepatitis B Virus (HBV) Mutations in HIV and HBV Co-Infected Individuals	3.45pm 4.00pm	Zou J - Mother to Infant Hepatitis C Virus Transmission	3.45pm 4.00pm	Wirkenheiser C - Building Blocks, Building Capacity: Working Together Towards Youth-Driven HCV Programs	3.45pm 4.00pm	Gilles M - From Policy to Primary Care: Tenacity the Vital Ingredient in Negotiating the Delivery of a Prison Based Hep C Treatment Program
4.05pm 4.20pm	Sievert B - Management of Anaemia, Neutropenia, and Thrombocytopenia	4.00pm 4.15pm	Bartholomeusz A - Molecular Modelling of Hepatitis B Virus Polymerase: Characterisation of Adefovir Resistance	4.00pm 4.15pm	Tawk H - The Prevalence of Hepatitis B in 2120 Patients Undergoing Endoscopy in an Australian Hospital and their Risk Factors for Infection	4.00pm 4.15pm	Jewell S - Testing and Diagnosis: Infecting Drug Users Experience Compared to National Policy	4.00pm 4.15pm	Morrison J - Developing the Capacity of the Aboriginal Health Sector to Deal with the Expanding Epidemic of Hepatitis C
4.20pm 4.35pm	Polis S - Reducing Treatment Related Morbidity	4.15pm 4.30pm	Bartholomeusz A - Functional Analysis of the Hepatitis B Virus RTL801 Mutant Selected in Patients with Severe Hepatitis During Long Term Lamivudine Therapy	4.15pm 4.30pm	Lang C - The Short Form-36 (SF-36) Does Not Identify Significant Impairments in Quality of Life Due to Symptom Clusters in People Living with Chronic Hepatitis C Infection	4.15pm 4.30pm	Waller LJ - Is It My Hep C?	4.15pm 4.30pm	Macdonald V - Predictors of Completion of a Hepatitis B Vaccination Schedule at a Primary Health Care Facility in Kings Cross, Sydney
4.35pm 5.00pm	Questions & discussion	4.30pm 4.45pm	Chang JJ - Reduced HBV-Specific CD4+ T-Cell Responses in HIV-1 HBV Co-Infected Individuals Receiving HBV-Active Antiretroviral Therapy	4.30pm 4.45pm	Totten L - The Effects of Interferon and Ribavirin Treatment on Patient Perceptions of Coping	4.30pm 4.45pm	Leonard PJ - My Life as a Doctor with Chronic Hepatitis C: The Psychosocial Impact of Chronic Illness and the Development of Resilience	4.30pm 4.45pm	Pritchard-Jones J & Gray D - Developing the Second Area Health Plan - Identifying the Needs and Getting Commitment from a Range of Services
5.00pm	Close	4.45pm 5.00pm	Vickery K - The Therapeutic Use of a DNA Vaccine Containing T-Cell Epitopes of Duck Hepatitis B Virus (DHBV)	4.45pm 5.00pm	Macdonald G - General Practitioner HCV Training Needs Survey: A Summary of Results	4.45pm 5.00pm	Clarke KC - Community Participation in the Media	4.45pm 5.00pm	Questions and Discussion
7.00pm	Conference Dinner - Old Parliament House								

**THURSDAY 2 SEPTEMBER 2004**

FULL CONFERENCE PROGRAM

THURSDAY 2 SEPTEMBER 2004

7.30am Registration							
9.00am - 10.30am		Symposium - Basic Science - HCV Protective Immunity and Vaccine development	Concurrent - Epidemiology & Social Research - Understanding Hepatitis C	Concurrent - Clinical Medicine - Clinical Outcomes in Hepatitis B & C	Symposium Public Health: Towards the control of Hepatitis B		
		Bradman Theatre Chairs: Rosemary French & Ian Ramshaw	Menzies Theatre Chairs: Stuart Loveday & Max Hopwood	Nicholls Theatre Chairs: Geoffrey Farrell & Ed Gane	Sutherland Theatre Chairs: John Hornell & Cindy Shannon		
9.00am - 9.20am	Lloyd A - Immunity against Hepatitis C in Highly Exposed Populations	9.00am - 9.15am	Richmond J - What are the Hepatitis C Knowledge and Attitudes of People with Hepatitis C	9.00am - 9.15am	McCaughan Geoffrey - Surgical Resection Versus Transplantation in the Treatment of Hepatocellular Carcinoma	9.00am - 9.20am	Bullen C - The New Zealand Hepatitis B Screening Programme: Screening Coverage, Findings and Key Learnings
9.20am - 9.40am	Eric Gowans: Dendritic cell vaccination strategies for HCV	9.15am - 9.30am	Treloar - C - Clinical Markers and Living with Hepatitis C	9.15am - 9.30am	Matthews G - Improvement in Treatment Outcomes Amongst HIV/HCV Coinfected Individuals Treated Within a Tertiary Hospital Clinic Since 2000	9.20am - 9.35am	Locarnini S - Prevalence of HBsAG Mutants and Impact of Hepatitis B Infant Immunisation in Four Pacific Island Countries
		9.30am - 9.45am	Nguyen O - So What's the Big Deal Anyway? How Do We Make Hepatitis C a Priority Among Ethnic-Vietnamese Injectors	9.30am - 9.45am	Matthews G - Virological Outcomes After Tenofovir Administration for HIV/HBV Coinfection	9.35am - 9.50am	Lai M - The Taiwan Experience
9.40am - 10.00am	Qiao M - Hepatitis C Virus-Like Particles as A Vaccine Candidate for Hepatitis C	9.45am - 10.00am	Doab A - Hepatitis C Knowledge, Attitudes and Barriers to Treatment in Active Injecting Drug Users	9.45am - 10.00am	Coverdale S - Demographic and Clinical Characteristics of Patients Presenting to a Tertiary Liver Clinic: What Difference a Decade Makes	9.50am - 10.05am	Hipgrave D - Regional Perspectives on Long Term Control of Hepatitis B Infection
10.00am - 10.20am	Jillbert A - DNA Vaccination Strategies for Hepatitis Viruses	10.00am - 10.15am	Polis S - Women's Perception of Antenatal Screening for Hepatitis B and Hepatitis C Virus	10.00am - 10.15am	Thein H - The Impact of Interferon-Based Therapy on Neurocognitive Function and Health-Related Quality of Life in Chronic Hepatitis C	10.05am - 10.30am	Questions & discussion
10.20am - 10.30am	Questions & discussion	10.15am - 10.30am	Martin L & Cao W - Who is Calling? Analysis of 8 Years of Calls to a Hepatitis C Telephone Information and Support Line	10.15am - 10.30am	Bowden S - Hepatitis C Virus Genotypes: Determination of Unusual Genotypes and Response to Therapy		

10.30am - 11.00am	Morning Tea in the Exhibition & Poster Area - Exhibition Hall		
11.00am - 12.30am	<b>Plenary - Coinfection</b>		
	Royal Theatre Chairs: Margaret Hellard & Martyn French		
11.00am - 11.30am	Sharon Lewin, Director of the Alfred Hospital Infectious Diseases Unit Immunopathogenesis of Viral Hepatitis/HIV Co-infection		
11.30am - 12.00pm	Greg Dore, Head of the Viral Hepatitis Program, National Centre in HIV Epidemiology and Clinical Research Natural History of Viral Hepatitis/HIV Co-infection		
12.00pm - 12.30pm	Joe Sasadeusz, Infectious Diseases Physician, Royal Melbourne Hospital Therapeutic Advances in Viral Hepatitis/HIV Co-infection		
12.30pm - 1.30pm	Lunch in the Exhibition & Poster Area - Exhibition Hall		
1.30pm - 3.00pm	<b>Plenary - Marginalised Populations</b>		<b>Concurrent - Basic Science - Model Systems &amp; Host Response</b>
	Royal Theatre Chairs: Charles Henderson & Michael Levy		Derwent Room Chairs: Stephen Locarnini & Eric Gowans
1.30pm - 2.00pm	Chris Cunningham, Professor of Maori Health & Director of the Research Centre for Maori Health & Development, Massey University, Wellington, New Zealand	1.30pm - 1.50pm	Gale M - Viral control of IRF3 Determines Host Permissiveness to HCV RNA Replication
	Maori Health and Hepatitis B	1.50pm - 2.04pm	McCaughan Geoff W - Microarray Analysis of Intrahepatic Gene Expression at Different Stages of Chronic HCV Infection
2.00pm - 2.30pm	Michael Doyle, Indigenous Projects Officer at the Hepatitis Council of Western Australia	2.04pm - 2.18pm	Vietheer PTK (TBI) - Development of Chimeric Hepatitis B Virus-Like Particles for the Delivery of Foreign Epitopes Derived from Hepatitis C Virus
	The Hepatitis C Response Among Indigenous Australians	2.18pm - 2.32pm	Drummer HE - Identification of a Hydrophobic Heptad Repeat in the Membrane-Proximal Region of HCV E2 Necessary for E1 and E2 Heterodimerization and Viral Entry



2.30pm - 3.00pm	Andrew Lloyd, Head of the Inflammation Research Unit, School of Medical Sciences, University of NSW	2.32pm - 2.46pm	Beard MR - Alcohol Metabolism Enhances HCV Replication in Vitro
	Enhancing Hepatitis C Treatment and Care in Prison Populations	2.46pm - 3.00pm	Gowans EJ - GBV-B Infection in the Marmoset; A Surrogate Model of HCV
3.00pm - 3.30pm	Afternoon Tea in the Exhibition & Poster Area - Exhibition Hall		
<b>Closing Session</b>			
3.30pm - 5.00pm	Royal Theatre Chair: Greg Dore		
3.30pm - 4.00pm	Geoff McCaughan, Director of the AW Morrow/GE Liver Centre at Royal Prince Alfred Hospital, Sydney Highlights from the conference program		
4.00pm - 4.20pm	Lorraine Breust, Director of the Hepatitis C Section of the Department of Health and Ageing, Canberra Strategic Directions for Australia's Response to Hepatitis C		
4.20pm - 4.50pm	Professor Robert Batey, Chair of the Hepatitis Sub-committee of the Ministerial Advisory Committee on AIDS, Sexual Health and Hepatitis Are We Heading in the Right Direction in Australia?		
4.50pm - 5.00pm	Greg Dore, Convenor of the 4th Australasian Hepatitis C Conference		
5.00pm	Close		